{"id":"bromfenac-0-09-eyedrops","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation or stinging"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Corneal erosion or keratitis"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a topical NSAID eyedrop, bromfenac penetrates ocular tissues and suppresses COX-1 and COX-2 enzymes, thereby decreasing prostaglandin production. This reduces inflammatory mediators responsible for pain, swelling, and inflammation following ocular surgery or in inflammatory eye conditions. The 0.09% formulation is designed for optimal ocular bioavailability and anti-inflammatory efficacy.","oneSentence":"Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation in the eye.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:42:40.260Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Postoperative inflammation and pain following ocular surgery"},{"name":"Ocular inflammation associated with allergic conjunctivitis or other inflammatory eye conditions"}]},"trialDetails":[{"nctId":"NCT07178639","phase":"NA","title":"Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract Surgery","status":"RECRUITING","sponsor":"Nemocnice Kolín","startDate":"2025-08-01","conditions":"Macular Oedema, Cataract Surgery, NSAID (Non-Steroidal Anti-Inflammatory Drug)","enrollment":150},{"nctId":"NCT03317847","phase":"PHASE4","title":"Bromfenac Versus Dexamethasone After Cataract Surgery","status":"COMPLETED","sponsor":"Azienda USL Reggio Emilia - IRCCS","startDate":"2017-10-16","conditions":"Inflammation Eye","enrollment":92},{"nctId":"NCT02137161","phase":"PHASE4","title":"Bromfenac to Reduce Inflammation in Patients With Pseudoexfoliation Syndrome After Cataract Surgery","status":"COMPLETED","sponsor":"Azienda USL Reggio Emilia - IRCCS","startDate":"2013-11","conditions":"Cataract, Pseudoexfoliation Syndrome","enrollment":62},{"nctId":"NCT06785090","phase":"PHASE4","title":"Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery","status":"COMPLETED","sponsor":"Inas Abd","startDate":"2023-05-01","conditions":"Cataract, Cystoid Macular Edema After Phacoemulsification","enrollment":87},{"nctId":"NCT05158699","phase":"PHASE3","title":"Effectiveness of Periocular Drug Injection in CATaract Surgery","status":"TERMINATED","sponsor":"Luigi Rondas","startDate":"2021-10-13","conditions":"Macular Edema, Cystoid Macular Edema, Retinal Disease","enrollment":628},{"nctId":"NCT06130384","phase":"PHASE4","title":"Pain Reduction With Topical Bromfenac Versus Artificial Tear After Intravitreal Injection.","status":"COMPLETED","sponsor":"Wills Eye","startDate":"2021-03-01","conditions":"Pain, Intravitreal Injection, Pain, Acute","enrollment":97},{"nctId":"NCT04343222","phase":"PHASE4","title":"Control of Pain in Intravitreal Injections Using Topical NSAIDs","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2019-06-27","conditions":"Intravitreal Injections, IVI","enrollment":46},{"nctId":"NCT05715385","phase":"PHASE4","title":"Comparison of Treatments in Diabetic Macular Edema","status":"COMPLETED","sponsor":"Babasaheb Ambedkar Memorial Hospital","startDate":"2014-11","conditions":"Diabetic Macular Edema","enrollment":60},{"nctId":"NCT04940338","phase":"PHASE4","title":"PCME Prevention in Patients With NPDR","status":"COMPLETED","sponsor":"Klinički Bolnički Centar Zagreb","startDate":"2021-05-01","conditions":"Cystoid Macular Edema Following Cataract Surgery","enrollment":90},{"nctId":"NCT01310127","phase":"PHASE4","title":"Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1%","status":"COMPLETED","sponsor":"Toyos Clinic","startDate":"2010-11","conditions":"Inflammation, Pseudophakia","enrollment":23},{"nctId":"NCT01535443","phase":"PHASE1","title":"Safety and Tolerability of PRO-155 Ophthalmic Solution 0.09% in Healthy Volunteers.","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2011-09","conditions":"Inflammation, Cataract","enrollment":35},{"nctId":"NCT01657266","phase":"PHASE2","title":"Efficacy and Safety of PRO-155 Versus Nevanac in Post Phacoemulsification","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2013-12","conditions":"Cataract, Phacoemulsification Cataract Surgery","enrollment":160},{"nctId":"NCT03597867","phase":"PHASE3","title":"PGE2 Levels in Patient Treated With NSAIDs","status":"COMPLETED","sponsor":"University of Trieste","startDate":"2018-04-25","conditions":"Ocular Inflammation","enrollment":104},{"nctId":"NCT01774474","phase":"PHASE3","title":"PRevention of Macular EDema After Cataract Surgery","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2013-07-10","conditions":"Cystoid Macular Edema, Cataract, Diabetes Mellitus","enrollment":1127},{"nctId":"NCT00438243","phase":"PHASE2","title":"Pilot Study of the Effect of Topical Bromfenac Ophthalmic Solution 0.09%in Patients With Acute Post-operative Cystoid Macular Edema.","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2008-05","conditions":"Cystoid Macular Edema","enrollment":""},{"nctId":"NCT01475877","phase":"","title":"Bromday Versus Nevanac Eye Drops to Control Pain Following Photorefractive Keratectomy","status":"COMPLETED","sponsor":"Virdi Eye Clinic","startDate":"2011-05","conditions":"Myopia","enrollment":20},{"nctId":"NCT00703781","phase":"PHASE3","title":"Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2008-06","conditions":"Cataract","enrollment":126},{"nctId":"NCT02361645","phase":"PHASE3","title":"NSAIDs and PGE2 Levels in Vitrectomy Patients","status":"COMPLETED","sponsor":"Università degli Studi di Brescia","startDate":"2014-03","conditions":"Vitreous Inflammation","enrollment":70},{"nctId":"NCT00585975","phase":"PHASE2","title":"Efficacy and Safety of Bromfenac Ophthalmic Solution","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2007-10","conditions":"Cataract Surgery","enrollment":568},{"nctId":"NCT00853970","phase":"PHASE3","title":"Efficacy Study of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2009-02","conditions":"Pain, Inflammation","enrollment":299},{"nctId":"NCT00704418","phase":"PHASE3","title":"Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2008-06","conditions":"Cataract","enrollment":156},{"nctId":"NCT00828477","phase":"PHASE4","title":"Evaluation of Comfort With Xibrom (Bromfenac Ophthalmic Solution)0.09% and Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Following Selective Laser Trabeculoplasty (SLT)","status":"COMPLETED","sponsor":"Bp Consulting, Inc","startDate":"2009-01","conditions":"Intraocular Pressure","enrollment":25},{"nctId":"NCT00491166","phase":"PHASE1","title":"Safety Study of Bromfenac Ophthalmic Solution in Subjects With Diffuse Diabetic Macular Edema (DME) Refractory to Laser","status":"UNKNOWN","sponsor":"Ophthalmic Consultants of Boston","startDate":"2007-06","conditions":"Diabetic Macular Edema","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Bromfenac 0.09% eyedrops","genericName":"Bromfenac 0.09% eyedrops","companyName":"Università degli Studi di Brescia","companyId":"universit-degli-studi-di-brescia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation in the eye. Used for Postoperative inflammation and pain following ocular surgery, Ocular inflammation associated with allergic conjunctivitis or other inflammatory eye conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}